| Budget Amount *help |
¥25,610,000 (Direct Cost: ¥19,700,000、Indirect Cost: ¥5,910,000)
Fiscal Year 2015: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
Fiscal Year 2013: ¥13,520,000 (Direct Cost: ¥10,400,000、Indirect Cost: ¥3,120,000)
|
|---|
| Outline of Final Research Achievements |
Primary aldosteronism (PA) is the most common and surgically curable form of endocrine hypertension, accounting for 5%-10% of all patients with hypertension. Approximately 60% patients with PA exhibit bilateral form causing aldosterone hypersecretion and require medical treatment with mineralocorticoid receptor antagonists. The remaining 40% exhibit the unilateral form causing hypersecretion, e.g., aldosterone-producing adenoma (APA); in these patients, hypertension and hyperaldosteronism can be cured by unilateral laparoscopic adrenalectomy. Therefore, an accurate method for distinguishing unilateral from bilateral adrenal disease is critical for patients who wish to pursue the surgical option. Aldosterone synthase (CYP11B2) is responsible for the majority of cases clinically diagnosed as primary aldosteronism. CYP11B2 is highly homologous to 11β-hydroxylase (CYP11B1). In this study, we have developed a PET/SPECT imaging probe with higher selectivity for CYP11B2 than CYP11B1.
|
